Mesenchymal Stem Cell Priming: Fine-tuning Adhesion and Function

Stem Cell Reviews and Reports

Volumn 10, Issue 4, 2014, Pages 587-599

  Kavanagh, Dean P J ^a   Robinson, Joseph ^a   Kalia, Neena ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cell adhesion; Cell recruitment; Cell therapy; Cytokines; Cytotherapy; Mesenchymal stem cells; Stem cells

Indexed keywords

ANIMAL; CELL ADHESION; CYTOLOGY; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; PHYSIOLOGY; TISSUE ENGINEERING;

ANIMALS; CELL ADHESION; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; TISSUE ENGINEERING;

EID: 84907860660     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-014-9510-7     Document Type: Article

References (133)

1. Dominici, M., et al. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. the international society for cellular therapy position statement. Cytotherapy, 8(4), 315–7.
2. Sohn, R., & Gussoni, E. (2004). Stem cell therapy for muscular dystrophy. Expert Opinion on Biological Therapy, 4(1), 1–9.
3. Fiorina, P., et al. (2009). Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type one diabetes. The Journal of Immunology, 183(2), 993–1004.
4. Silva, G. V., et al. (2005). Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation, 111(2), 150–156.
5. Friedenstein, A. J., et al. (1974). Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. cloning in vitro and retransplantation in vivo. Transplantation, 17(4), 331–40.
6. Caplan, A. I. (1991). Mesenchymal stem cells. Journal of Orthopaedic Research, 9(5), 641–50.
7. Lanza, R.P., Gearhart, J., Hogan, B. (2006). Essentials of stem cell biology. illustrated, abridged ed. (p206). Academic Press
8. Kohyama, J., et al. (2001). Brain from bone: efficient “meta-differentiation” of marrow stroma-derived mature osteoblasts to neurons with Noggin or a demethylating agent. Differentiation, 68(4–5), 235–44.
9. Malgieri, A., et al. (2010). Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. International Journal of Clinical and Experimental Medicine, 3(4), 248–69.
10. Cao, H., et al. (2010). Mesenchymal stem cells derived from human umbilical cord ameliorate ischemia/reperfusion-induced acute renal failure in rats. Biotechnology Letters, 32(5), 725–732.
11. Summer, R., et al. (2007). Isolation of an adult mouse lung mesenchymal progenitor cell population. American Journal of Respiratory Cell and Molecular Biology, 37(2), 152–9.
12. Huang, Y., et al. (2009). Kidney-derived stromal cells modulate dendritic and T cell responses. Journal of the American Society of Nephrology, 20(4), 831–41.
13. Zuk, P. A., et al. (2002). Human adipose tissue is a source of multipotent stem cells. Molecular Biology of the Cell, 13(12), 4279–4295.
14. Tomar, G. B., et al. (2010). Human gingiva-derived mesenchymal stem cells are superior to bone marrow-derived mesenchymal stem cells for cell therapy in regenerative medicine. Biochemical and Biophysical Research Communications, 393(3), 377–83.
15. Houlihan, D. D., et al. (2012). Isolation of mouse mesenchymal stem cells on the basis of expression of Sca-1 and PDGFR-alpha. Nature Protocols, 7(12), 2103–11.
16. Krampera, M., et al. (2013). Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy, 15(9), 1054–1061.
17. Peister, A., et al. (2004). Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood, 103(5), 1662–8.
18. Morikawa, S., et al. (2009). Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. Journal of Experimental Medicine, 206(11), 2483–96.
19. Ren, G., et al. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2(2), 141–50.
20. Ren, G., et al. (2009). Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells, 27(8), 1954–62.
21. Le Blanc, K., et al. (2003). HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Experimental Hematology, 31(10), 890–6.
22. Griffin, M. D., et al. (2013). Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? Immunology and Cell Biology, 91(1), 40–51.
23. Camp, D. M., et al. (2009). Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson's disease. Journal of Neuroinflammation, 6, 17.
24. Huang, X. P., et al. (2010). Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation, 122(23), 2419–29.
25. Isakova, I. A., et al. (2010). Cell-dose-dependent increases in circulating levels of immune effector cells in rhesus macaques following intracranial injection of allogeneic MSCs. Experimental Hematology, 38(10), 957–967.
26. Eliopoulos, N., et al. (2005). Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood, 106(13), 4057–65.
27. Seifert, M., et al. (2012). Detrimental effects of rat mesenchymal stromal cell pre-treatment in a model of acute kidney rejection. Frontiers in Immunology, 3, 202.
28. Schu, S., et al. (2012). Immunogenicity of allogeneic mesenchymal stem cells. Journal of Cellular and Molecular Medicine, 16(9), 2094–103.
29. Liotta, F., et al. (2008). Toll-like receptors three and four are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells, 26(1), 279–89.
30. Augello, A., et al. (2005). Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death one pathway. European Journal of Immunology, 35(5), 1482–90.
31. Gonzalez-Rey, E., et al. (2009). Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut, 58(7), 929–939.
32. Togel, F., et al. (2005). Renal SDF-1 signals mobilization and homing of CXCR4-positive cells to the kidney after ischemic injury. Kidney International, 67(5), 1772–84.
33. Suga, H., et al. (2009). IFATS collection: Fibroblast growth factor-two-induced hepatocyte growth factor secretion by adipose-derived stromal cells inhibits postinjury fibrogenesis through a c-Jun N-terminal kinase-dependent mechanism. Stem Cells, 27(1), 238–49.
34. Hou, X., et al. (2010). Erythropoietin augments the efficacy of therapeutic angiogenesis induced by allogenic bone marrow stromal cells in a rat model of limb ischemia. Molecular Biology Reports, 37(3), 1467–75.
35. Rehman, J., et al. (2004). Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation, 109(10), 1292–8.
36. Hung, S. C., et al. (2007). Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells, 25(9), 2363–70.
37. Choi, H., et al. (2011). Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-kappaB signaling in resident macrophages. Blood, 118(2), 330–8.
38. Walenda, T., et al. (2011). Synergistic effects of growth factors and mesenchymal stromal cells for expansion of hematopoietic stem and progenitor cells. Experimental Hematology, 39(6), 617–28.
39. Nemeth, K., et al. (2009). Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-ten production. Nature Medicine, 15(1), 42–49.
40. Shah, K. (2012). Mesenchymal stem cells engineered for cancer therapy. Advanced Drug Delivery Reviews, 64(8), 739–48.
41. Dai, T., et al. (2013). Preparation and drug release mechanism of CTS-TAX-NP-MSCs drug delivery system. International Journal Pharmaceutics, 456(1),186–194.
42. Cavarretta, I. T., et al. (2010). Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Molecular Therapy, 18(1), 223–31.
43. Chen, T. S., et al. (2011). Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs. Journal of Translational Medicine, 9, 47.
44. Yeo, R. W., et al. (2013). Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Advanced Drug Delivery Reviews, 65(3), 336–41.
45. van Dommelen, S. M., et al. (2012). Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. Journal of Controlled Release, 161(2), 635–644.
46. Mohit, E., & Rafati, S. (2013). Biological delivery approaches for gene therapy: strategies to potentiate efficacy and enhance specificity. Molecular Immunology, 56(4), 599–611.
47. Chapel, A., et al. (2003). Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. The Journal of Gene Medicine, 5(12), 1028–1038.
48. Ortiz, L. A., et al. (2003). Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proceedings of the National Academy of Sciences, 100(14), 8407–8411.
49. Chang, P., et al. (2013). Multi-therapeutic effects of human adipose-derived mesenchymal stem cells on radiation-induced intestinal injury. Cell Death and Disease, 4, e685.
50. Aldridge, V., et al. (2012). Human mesenchymal stem cells are recruited to injured liver in a β1-integrin and CD44 dependent manner. Hepatology, 56(3), 1063–1073.
51. Eggenhofer, E., et al. (2012). Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Frontiers Immunology, 3, 297.
52. Ramirez, M., et al. (2006). Mobilisation of mesenchymal cells into blood in response to skeletal muscle injury. British Journal of Sports Medicine, 40(8), 719–22.
53. Rochefort, G. Y., et al. (2006). Multipotential mesenchymal stem cells are mobilized into peripheral blood by hypoxia. Stem Cells, 24(10), 2202–8.
54. Wang, Y., et al. (2006). Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth factors in patients with acute ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart, 92(6), 768–74.
55. Wang, N., et al. (2012). Mesenchymal stem cells attenuate peritoneal injury through secretion of TSG-6. PLoS ONE, 7(8), e43768.
56. Lee, R. H., et al. (2009). Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell, 5(1), 54–63.
57. Danchuk, S., et al. (2011). Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-alpha-induced protein 6. Stem Cell Research Therapy, 2(3), 27.
58. Roddy, G. W., et al. (2011). Action at a distance: systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-α stimulated gene/protein six. Stem Cells, 29(10), 1572–1579.
59. Scruggs, B. A., et al. (2013). Multipotent stromal cells alleviate inflammation, neuropathology, and symptoms associated with globoid cell leukodystrophy in the twitcher mouse. Stem Cells, 31(8), 1523–34.
60. Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001). Long-circulating and target-specific nanoparticles: theory to practice. Pharmacological Reviews, 53(2), 283–318.
61. Schrepfer, S., et al. (2007). Stem cell transplantation: the lung barrier. Transplantation Proceedings, 39(2), 573–6.
62. Chamberlain, G., et al. (2007). Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells, 25(11), 2739–49.
63. Majumdar, M. K., et al. (2003). Characterization and functionality of cell surface molecules on human mesenchymal stem cells. Journal of Biomedical Science, 10, 228–241.
64. Lo Surdo, J., & Bauer, S. R. (2012). Quantitative approaches to detect donor and passage differences in adipogenic potential and clonogenicity in human bone marrow-derived mesenchymal stem cells. Tissue Engineering. Part C, Methods, 18(11), 877–89.
65. De Ugarte, D. A., et al. (2003). Differential expression of stem cell mobilization-associated molecules on multi-lineage cells from adipose tissue and bone marrow. Immunology Letters, 89(2–3), 267–70.
66. Pevsner-Fischer, M., Levin, S., & Zipori, D. (2011). The origins of mesenchymal stromal cell heterogeneity. Stem Cell Reviews, 7(3), 560–8.
67. Rüster, B., et al. (2006). Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood, 108, 3938–3944.
68. Aziz, K. A., et al. (2000). Involvement of CD44-hyaluronan interaction in malignant cell homing and fibronectin synthesis in hairy cell leukemia. Blood, 96(9), 3161–3167.
69. Alves, C. S., et al. (2008). The dual role of CD44 as a functional P-selectin ligand and fibrin receptor in colon carcinoma cell adhesion. American Journal of Physiology - Cell Physiolog, 294(4), C907–C916.
70. Dimitroff, C. J., et al. (2000). A distinct glycoform of CD44 is an L-selectin ligand on human hematopoietic cells. Proceedings of the National Academy of Sciences of the United States of America, 97(25), 13841–6.
71. Burdick, M. M., et al. (2006). HCELL is the major E- and L-selectin ligand expressed on LS174T colon carcinoma cells. Journal of Biological Chemistry, 281(20), 13899–13905.
72. Avigdor, A., et al. (2004). CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood, 103(8), 2981–9.
73. Thankamony, S. P., & Sackstein, R. (2011). Enforced hematopoietic cell E- and L-selectin ligand (HCELL) expression primes transendothelial migration of human mesenchymal stem cells. Proceedings of the National Academy of Sciences, 108(6), 2258–2263.
74. Ciuculescu, F., et al. (2011). Variability in chemokine-induced adhesion of human mesenchymal stromal cells. Cytotherapy, 13(10), 1172–9.
75. Herrera, M. B., et al. (2007). Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney International, 72(4), 430–41.
76. Ip, J. E., et al. (2007). Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor four for myocardial migration and engraftment. Molecular Biology of the Cell, 18, 2873–2882.
77. Schreiber, T.D., et al.(2009). The integrin {alpha} 9 {beta} 1 on hematopoietic stem and progenitor cells: involvement in cell adhesion, proliferation and differentiation. Haematologica, p. [epub ahead of print].
78. Langer, H. F., et al. (2009). Platelet derived bFGF mediates vascular integrative mechanisms of mesenchymal stem cells in vitro. Journal of Molecular and Cellular Cardiology, 47(2), 315–25.
79. Gao, J., et al. (2001). The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells, Tissues, Organs, 169(1), 12–20.
80. Shi, M., et al. (2007). Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematologica, 92(7), 897–904.
81. Bhakta, S., Hong, P., & Koc, O. (2006). The surface adhesion molecule CXCR4 stimulates mesenchymal stem cell migration to stromal cell-derived factor-1 in vitro but does not decrease apoptosis under serum deprivation. Cardiovascular Revascularization Medicine, 7(1), 19–24.
82. Duijvestein, M., et al. (2011). Pretreatment with interferon-gamma enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells, 29(10), 1549–58.
83. Kavanagh, D. P. J., & Kalia, N. (2011). Hematopoietic stem cell homing to injured tissues. Stem Cell Reviews and Reports, 7(3), 672–682.
84. Fan, H., et al. (2012). Pre-treatment with IL-1beta enhances the efficacy of MSC transplantation in DSS-induced colitis. Cellular and molecular immunology, 9(6), 473–81.
85. Lalu, M. M., et al. (2012). safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE, 7(10), e47559.
86. Wang, L., et al. (2013). IFN-γ and TNF-α synergistically induce mesenchymal stem cell impairment and tumorigenesis via NFκB signaling. Stem Cells, 31(7), 1383–1395.
87. Ceradini, D. J., et al. (2004). Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nature Medicine, 10(8), 858–64.
88. Hu, X., et al. (2011). Hypoxic preconditioning enhances bone marrow mesenchymal stem cell migration via Kv2.1 channel and FAK activation. American Journal of Physiology. Cell Physiology, 301(2), C362–72.
89. Rosova, I., et al. (2008). Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells, 26(8), 2173–82.
90. Wei, N., et al. (2013). Delayed intranasal delivery of hypoxic-preconditioned bone marrow mesenchymal stem cells enhanced cell homing and therapeutic benefits after ischemic stroke in mice. Cell Transplantation, 22(6), 977–91.
91. Crowder, S. W., et al. (2013). Passage-dependent cancerous transformation of human mesenchymal stem cells under carcinogenic hypoxia. FASEB Journal, 27(7), 2788–98.
92. Estrada, J. C., et al. (2012). Culture of human mesenchymal stem cells at low oxygen tension improves growth and genetic stability by activating glycolysis. Cell Death and Differentiation, 19(5), 743–755.
93. Sarkar, D., et al. (2010). Engineered mesenchymal stem cells with self-assembled vesicles for systemic cell targeting. Biomaterials, 31(19), 5266–74.
94. Sarkar, D., et al. (2008). Chemical engineering of mesenchymal stem cells to induce a cell rolling response. Bioconjugate Chemistry, 19(11), 2105–9.
95. Sarkar, D., et al. (2011). Engineered cell homing. Blood, 118(25), e184–91.
96. Sackstein, R., et al. (2008). Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nature Medicine, 14(2), 181–7.
97. Huang, J., et al. (2010). Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circulation Research, 106(11), 1753–62.
98. Gheisari, Y., et al. (2012). Genetic modification of mesenchymal stem cells to overexpress CXCR4 and CXCR7 does not improve the homing and therapeutic potentials of these cells in experimental acute kidney injury. Stem Cells and Development, 21(16), 2969–80.
99. Cheng, Z., et al. (2008). Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Molecular Therapy, 16(3), 571–9.
100. Phillips, M. I., & Tang, Y. L. (2008). Genetic modification of stem cells for transplantation. Advanced Drug Delivery Reviews, 60(2), 160–172.
101. Belay, E., et al. (2010). Novel hyperactive transposons for genetic modification of induced pluripotent and adult stem cells: a nonviral paradigm for coaxed differentiation. Stem Cells, 28(10), 1760–1771.
102. Zielske, S. P., Livant, D. L., & Lawrence, T. S. (2009). Radiation increases invasion of gene-modified mesenchymal stem cells into tumors. International Journal of Radiation Oncology, Biology, and Physics, 75(3), 843–53.
103. Klopp, A. H., et al. (2007). Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Research, 67(24), 11687–95.
104. Liang, X., et al. (2011). The low-dose ionizing radiation stimulates cell proliferation via activation of the MAPK/ERK pathway in rat cultured mesenchymal stem cells. Journal of Radiation Research, 52(3), 380–6.
105. Burks, S.R., et al. (2013). Noninvasive pulsed focused ultrasound allows spatiotemporal control of targeted homing for multiple stem cell types in murine skeletal muscle and the magnitude of cell homing can be increased through repeated applications. Stem Cells, 31(11), 2551–2560.
106. Ziadloo, A., et al. (2012). Enhanced homing permeability and retention of bone marrow stromal cells by noninvasive pulsed focused ultrasound. Stem Cells, 30(6), 1216–27.
107. Ghanem, A., et al. (2009). Focused ultrasound-induced stimulation of microbubbles augments site-targeted engraftment of mesenchymal stem cells after acute myocardial infarction. Journal of Molecular and Cellular Cardiology, 47(3), 411–418.
108. Yanai, A., et al. (2012). Focused magnetic stem cell targeting to the retina using superparamagnetic iron oxide nanoparticles. Cell Transplantation, 21(6), 1137–48.
109. Landazuri, N., et al. (2013). Magnetic Targeting of Human Mesenchymal Stem Cells with Internalized Superparamagnetic Iron Oxide Nanoparticles. Small, 9(23), 4017–4026.
110. Waterman, R. S., et al. (2010). A new Mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 Phenotype. PLoS ONE, 5(4), e10088.
111. Waterman, R. S., Henkle, S. L., & Betancourt, A. M. (2012). Mesenchymal stem cell one MSC1-Based therapy Attenuates Tumor growth whereas MSC2 treatment promotes tumor growth and Metastasis. PLoS ONE, 7(9), e45590.
112. Waterman, R. S., et al. (2012). Anti-inflammatory mesenchymal stem cells (MSC2) attenuate symptoms of painful diabetic peripheral neuropathy. Stem Cells Translational Medicine, 1(7), 557–65.
113. Boehm, U., et al. (1997). Cellular responses to interferon-gamma. Annual Review of Immunology, 15, 749–95.
114. Stagg, J., et al. (2006). Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood, 107(6), 2570–7.
115. English, K., et al. (2007). IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunology Letters, 110(2), 91–100.
116. Mellor, A. L., & Munn, D. H. (2000). Immunology at the maternal-fetal interface: lessons for T cell tolerance and suppression. Annual Review of Immunology, 18, 367–91.
117. Ge, W., et al. (2010). Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation, 90(12), 1312–20.
118. Spaggiari, G. M., et al. (2008). Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine two, three-dioxygenase and prostaglandin E2. Blood, 111(3), 1327–33.
119. Xu, G., et al. (2009). C/EBPbeta mediates synergistic upregulation of gene expression by interferon-gamma and tumor necrosis factor-alpha in bone marrow-derived mesenchymal stem cells. Stem Cells, 27(4), 942–8.
120. Zhang, S., et al. (2014). Interleukin 6 mediates the therapeutic effects of adipose-derived stromal/stem cells in lipopolysaccharide-induced acute lung injury. Stem Cells. doi:10.1002/stem.1632.
121. Nasir, G. A., et al. (2013). Mesenchymal stem cells and Interleukin-six attenuate liver fibrosis in mice. Journal of Translational Medicine, 11(1), 78.
122. Sheng, H., et al. (2008). A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Research, 18(8), 846–57.
123. Luo, Y., et al. (2012). Pretreating mesenchymal stem cells with interleukin-1beta and transforming growth factor-beta synergistically increases vascular endothelial growth factor production and improves mesenchymal stem cell-mediated myocardial protection after acute ischemia. Surgery, 151(3), 353–63.
124. Herrmann, J. L., et al. (2011). Transforming growth factor-alpha enhances stem cell-mediated postischemic myocardial protection. Annals of Thoracic Surgery, 92(5), 1719–25.
125. Wang, Y., et al. (2008). TGF-alpha increases human mesenchymal stem cell-secreted VEGF by MEK- and PI3-K- but not JNK- or ERK-dependent mechanisms. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 295(4), R1115–23.
126. Chen, H. Y., et al. (2012). The protective effect of 17beta-estradiol against hydrogen peroxide-induced apoptosis on mesenchymal stem cell. Biomedicine and Pharmacotherapy, 66(1), 57–63.
127. Noiseux, N., et al. (2012). Preconditioning of stem cells by oxytocin to improve their therapeutic potential. Endocrinology, 153(11), 5361–72.
128. Xie, X. X., et al. (2012). Transplantation of Mesenchymal stem cells preconditioned with hydrogen sulfide enhances repair of myocardial infarction in rats. Tohoku Journal of Experimental Medicine, 226(1), 29–36.
129. Nasir, G. A., et al. (2013). Mesenchymal stem cells and Interleukin-six attenuate liver fibrosis in mice. Journal of Translational Medicine, 11, 78.
130. Chen, S., et al. (2012). Ischemia postconditioning and mesenchymal stem cells engraftment synergistically attenuate ischemia reperfusion-induced lung injury in rats. Journal of Surgical Research, 178(1), 81–91.
131. Bianco, P., et al. (2013). The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nature Medicine, 19(1), 35–42.
132. Dreger, P., et al. (1995). Autologous progenitor cell transplantation: prior exposure to stem cell- toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood, 86(10), 3970–3978.
133. Blazar, B., et al. (1988). Augmentation of donor bone marrow engraftment in histoincompatible murine recipients by granulocyte/macrophage colony-stimulating factor. Blood, 71(2), 320–328.